Alvotech (ALVO) has a bullish thesis due to biosimilar drugs focus.

From Yahoo Finance: 2025-06-24 09:05:00

Alvotech (ALVO) has a bullish thesis due to its focus on developing affordable biosimilar drugs, with a proprietary facility and growing pipeline. Financially, the company is gaining traction but faces challenges with high debt and execution risks. Valuation is attractive, but complexities exist. Founder-CEO alignment and potential upside make it a compelling opportunity.

Compared to Medpace, Alvotech offers higher but riskier upside as a biotech-driven healthcare play despite debt and regulatory concerns. Hedge funds are increasingly interested in ALVO, with 10 portfolios holding the stock at the end of Q1. However, some AI stocks may offer more promising returns with lower downside risk.

Read more: Alvotech (ALVO): A Bull Case Theory